Viewing Study NCT00899093


Ignite Creation Date: 2025-12-25 @ 1:03 AM
Ignite Modification Date: 2026-03-12 @ 1:15 PM
Study NCT ID: NCT00899093
Status: TERMINATED
Last Update Posted: 2018-05-22
First Post: 2009-05-09
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy
Sponsor: Gynecologic Oncology Group
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Fallopian Tube Adenocarcinoma View
None Fallopian Tube Clear Cell Adenocarcinoma View
None Fallopian Tube Endometrioid Adenocarcinoma View
None Fallopian Tube Mucinous Adenocarcinoma View
None Fallopian Tube Serous Adenocarcinoma View
None Fallopian Tube Transitional Cell Carcinoma View
None Malignant Ovarian Brenner Tumor View
None Malignant Ovarian Clear Cell Tumor View
None Malignant Ovarian Endometrioid Tumor View
None Malignant Ovarian Mixed Epithelial Tumor View
None Malignant Ovarian Mucinous Tumor View
None Malignant Ovarian Neoplasm View
None Malignant Ovarian Serous Tumor View
None Malignant Ovarian Transitional Cell Tumor View
None Ovarian Adenocarcinoma View
None Primary Peritoneal Serous Adenocarcinoma View
None Stage IIIA Fallopian Tube Cancer View
None Stage IIIA Ovarian Cancer View
None Stage IIIA Primary Peritoneal Cancer View
None Stage IIIB Fallopian Tube Cancer View
None Stage IIIB Ovarian Cancer View
None Stage IIIB Primary Peritoneal Cancer View
None Stage IIIC Fallopian Tube Cancer View
None Stage IIIC Ovarian Cancer View
None Stage IIIC Primary Peritoneal Cancer View
None Stage IV Fallopian Tube Cancer View
None Stage IV Ovarian Cancer View
None Stage IV Primary Peritoneal Cancer View
None Undifferentiated Fallopian Tube Carcinoma View
None Undifferentiated Ovarian Carcinoma View
Keywords: